Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Megaloblastic Anemia Workup

  • Author: Paul Schick, MD; Chief Editor: Emmanuel C Besa, MD  more...
 
Updated: Apr 06, 2014
 

Approach Considerations

The anemia should be characterized. Pancytopenia and systemic impairment should be evaluated. The etiology of megaloblastosis should be identified.

Next

Initial Studies

Initial workup for megaloblastic anemia should include a complete blood count (CBC), RBC indices, peripheral smear, reticulocyte count, lactate dehydrogenase (LDH), indirect bilirubin, iron and ferritin assays, serum cobalamin and serum folate, and possibly an RBC folate evaluation.

LDH is usually markedly increased in severe megaloblastic anemia. Reticulocyte counts are inappropriately low, representing lack of production of RBCs due to massive intramedullary hemolysis. These findings are characteristics of ineffective hematopoiesis that occurs in megaloblastic anemia as well as in other disorders such as thalassemia major.

Peripheral smear morphology

A peripheral smear may reveal macroovalocytes, a characteristic of megaloblastosis. They should be distinguished from macrocytes that are not oval that can occur in liver disease and hypothyroidism. Polychromatophilic macrocytes, reticulocytes, and immature RBCs can be seen in hemolytic anemia and disorders associated with increased RBC production.

Single and multiple Howell-Jolly bodies, nuclear fragment, may be seen in RBCs. Cabot rings, remnants of mitotic spindles, may also be present in RBCs.

Nucleated RBCs and megaloblasts can be seen.

Smears may reveal hypersegmented neutrophils if at least 5% neutrophils have 5 or more lobes. Normal neutrophils contain 3-4 lobes.

Macrocytosis due to cobalamin or folate deficiencies may be masked in patients with iron deficiency. However, hypersegmented neutrophils can persist in iron deficiency.

Bone marrow aspiration

Bone marrow aspiration is usually not needed to make the diagnosis of vitamin B-12 deficiency. However, it can help rule out myelodysplasia and assess iron stores. The bone marrow is hypercellular with erythroid hyperplasia. Erythroid precursors have megaloblastic features being larger than normoblastic cells. In addition, nuclear maturation is immature relative to cytoplasmic maturation. Megaloblastic changes are most prominent in more mature RBC precursors. Giant bands, neutrophil precursers, can be present. Megakaryocytes may be large and hyperlobulated .

Bone marrow megaloblastic changes are reversed within 12 hours after treatment with cobalamin or folate, and bone marrow morphology appears to be normal within 2-3 days. Therefore, bone marrow aspiration, if necessary, should be performed as soon as possible and preferably before therapy.

Previous
Next

Primary Tests for B-12 and Folate Deficiencies

Serum B-12 (cobalamin)

Reference range: 200-900 pg/mL

  • Borderline: 180-250 pg/mL
  • Associated with anemia and neuropathy: < 180 mg/L
  • Diagnostic of B-12 deficiency: < 150 mg/L

The serum cobalamin level can be normal in the following circumstances:

  • In some inborn areas of cobalamin deficiency
  • Transcobalamin II (TC II) deficiency
  • Cobalamin deficiency due to nitrous oxide

Serum cobalamin levels may be low in the following circumstances:

  • Pregnancy
  • Oral contraceptives
  • Transcobalamin I (TC I) deficiency
  • Severe folic acid deficiency
  • Patients taking large doses of ascorbic acid

Serum folate

Reference range: 2.5-20 ng/mL

  • 5 ng/mL
  • Folate deficiency likely (overlap with normal): < 2.5 ng/mL –

The following should be considered:

  • Effect of diet: A single meal may falsely elevate serum folate levels to normal. Hence, blood should be drawn prior to transfusions, meals, and therapy to achieve accurate results.
  • Hemolysis: Might cause false positive results

RBC folate

Reference range: >140 ng/mL

  • Not affected by diet and reflects tissue stores (folate content is established early in RBC development)
  • Affected by hemolysis
  • Low in severe B-12 deficiency
  • Test is intricate and expensive

Serum for folate and cobalamin should be frozen and stored prior to meals or therapy if the tests cannot be performed within a reasonable timeframe.

Lab tests to confirm and distinguish B-12 and folate deficiencies

Serum homocysteine and methylmalonic acid (MMA) levels are helpful confirmatory tests for cobalamin and folate deficiencies. Both are increased in cobalamine deficiency. Homocysteine but not MMA is increased in folate deficiency. Homocysteine and MMA levels should be used if the clinical presentation and serum vitamin B-12 and folate levels are ambiguous.

The MMA level can be increased in the following circumstances:

  • End stage renal disease
  • Inborn error of methylmalonic acid metabolism

Serum homocysteine can be increased in the following circumstances:

  • Homocystinuria
  • Hyperhomocysteinemia
  • MTHFR C677T

Serum homocysteine can be decreased in the following circumstances:

  • A high rate of conversion back to methionine
  • Low production
  • A high rate of conversion of into sulfite/sulfate etc

Intrinsic factor (IF) blocking and parietal cell and antibodies

IF antibodies, type 1 and type 2, occur in 50% of patients with pernicious anemia and are specific for this disorder. Therefore, they can be used to confirm the diagnosis of pernicious anemia. Parietal cell antibody occurs in 90% of patients with pernicious anemia but can also occur in thyroid disease and other autoimmune disorders. Therefore, parietal cell antibodies are not specific for pernicious anemia.

A valuable test that is no longer available (Schilling test)

The value of a Schilling test (a radiometric test) is that it can confirm B-12 deficiency, can be done after patient has been given B-12 therapy, and can distinguish between pernicious anemia and failure in transport or ileal uptake. Unfortunately, the test is no longer available at most hospitals. The 3 parts to the Schilling test are as follows:

  1. First, radioactive cyanocobalamin is given orally and its urinary secretion is measured to estimate cobalamin uptake. Low urinary secretion suggests pernicious anemia, a failure in intestinal transport, defective uptake of cobalamin in the terminal ileum, or a blind loop syndrome.
  2. The second part is performed in the same manner, except that IF is given orally along with radioactive cyanocobalamin. If IF restores cobalamin uptake, the patient most likely has pernicious anemia. If not, an abnormality in cobalamin intestinal transport, defective absorption in the terminal ileum, or a blind loop syndrome might be responsible for the deficiency.
  3. In the third phase, the patient is treated with antibiotics before the administration of radioactive cyanocobalamin. If antibiotics restore cobalamin uptake, the patient most likely has a blind loop syndrome.
Previous
Next

Diagnostic Therapeutic Trial

If the results of the evaluation are ambiguous, a clinical trial of the effects of cobalamin therapy may be indicated. However, a clinical trial of folate is contraindicated if cobalamin deficiency has not been ruled out. The administration of folate to patients with cobalamin deficiencies may precipitate or worsen neurological impairment.

Previous
Next

Other Studies

Baseline iron studies and serum ferritin should be obtained since they may predict the need for iron therapy since iron stores can be consumed during cobalamin or folate therapy.

Radiographic imaging of the upper and lower gastrointestinal tract may be useful for detecting abnormalities that could cause a blind loop syndrome. These procedures also may detect defects in the terminal ileum that might interfere with cobalamin absorption.

Other tests that may be considered include the following:

  • With cobalamin deficiency, evaluate and rule out autoimmune disorders, Zollinger-Ellison syndrome, pancreatic insufficiency, fish tapeworm infestation, Imerslund-Grasbeck syndrome, Crohn disease, or ileal scarring.
  • With folate deficiency, evaluate evidence for malnutrition and alcoholism, sprue, chronic hemolysis, and exfoliative dermatitis.
  • Megaloblastic anemia
Previous
 
 
Contributor Information and Disclosures
Author

Paul Schick, MD Emeritus Professor, Department of Internal Medicine, Jefferson Medical College of Thomas Jefferson University; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital

Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Society of Hematology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ronald A Sacher, MB, BCh, FRCPC, DTM&H Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center

Ronald A Sacher, MB, BCh, FRCPC, DTM&H is a member of the following medical societies: American Association for the Advancement of Science, American Association of Blood Banks, American Society for Clinical Pathology, American Society of Hematology, College of American Pathologists, International Society on Thrombosis and Haemostasis, Royal College of Physicians and Surgeons of Canada, American Clinical and Climatological Association, International Society of Blood Transfusion

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: GSK Pharmaceuticals,Alexion,Johnson & Johnson Talecris,,Grifols<br/>Received honoraria from all the above companies for speaking and teaching.

Chief Editor

Emmanuel C Besa, MD Professor Emeritus, Department of Medicine, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University

Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American Society of Clinical Oncology, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, New York Academy of Sciences

Disclosure: Nothing to disclose.

Additional Contributors

Thomas H Davis, MD, FACP Associate Professor, Fellowship Program Director, Department of Internal Medicine, Section of Hematology/Oncology, Geisel School of Medicine at Dartmouth

Thomas H Davis, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American Association for Cancer Education, American College of Physicians, New Hampshire Medical Society, Phi Beta Kappa, Society of University Urologists

Disclosure: Nothing to disclose.

References
  1. Hoffman R, Benz EJ, Furie B, Shattil SJ. Hematology: Basic Principles and Practice. Philadelphia, Pa: Churchill Livingstone; 2009.

  2. Wang YH, Yan F, Zhang WB, et al. An investigation of vitamin B12 deficiency in elderly inpatients in neurology department. Neurosci Bull. 2009 Aug. 25(4):209-15. [Medline].

  3. Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw Hill; 2001.

  4. Singh NN. Vitamin B-12 Associated Neurological Diseases. Medscape Reference. Available at http://emedicine.medscape.com/article/1152670-overview. Accessed: February 18, 2014.

  5. Leishear K, Ferrucci L, Lauretani F, et al. Vitamin B12 and homocysteine levels and 6-year change in peripheral nerve function and neurological signs. J Gerontol A Biol Sci Med Sci. 2012 May. 67(5):537-43. [Medline].

  6. Dali-Youcef N, Andres E. An update on cobalamin deficiency in adults. QJM. 2009 Jan. 102(1):17-28. [Medline].

  7. Filioussi K, Bonovas S, Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia?. Aust Fam Physician. 2003 May. 32(5):383-4. [Medline].

  8. Gomber S, Dewan P, Dua T. Homocystinuria: a rare cause of megaloblastic anemia. Indian Pediatr. 2004 Sep. 41(9):941-3. [Medline].

  9. Borgna-Pignatti C, Azzalli M, Pedretti S. Thiamine-responsive megaloblastic anemia syndrome: long term follow-up. J Pediatr. 2009 Aug. 155(2):295-7. [Medline].

  10. Molloy AM, Kirke PN, Brody LC, Scott JM, Mills JL. Effects of folate and vitamin B12 deficiencies during pregnancy on fetal, infant, and child development. Food Nutr Bull. 2008 Jun. 29(2 Suppl):S101-11; discussion S112-5. [Medline].

  11. U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009 May 5. 150(9):626-31. [Medline].

  12. Andres E, Fothergill H, Mecili M. Efficacy of oral cobalamin (vitamin B12) therapy. Expert Opin Pharmacother. 2010 Feb. 11(2):249-56. [Medline].

  13. Dary O. Nutritional interpretation of folic acid interventions. Nutr Rev. 2009 Apr. 67(4):235-44. [Medline].

  14. Lawrence MA, Chai W, Kara R, Rosenberg IH, Scott J, Tedstone A. Examination of selected national policies towards mandatory folic acid fortification. Nutr Rev. 2009 May. 67 Suppl 1:S73-8. [Medline].

  15. Varela-Moreiras G, Murphy MM, Scott JM. Cobalamin, folic acid, and homocysteine. Nutr Rev. 2009 May. 67 Suppl 1:S69-72. [Medline].

  16. Mayo Clinic. Folate dosing. Mayoclinic.com. Available at http://www.mayoclinic.com/health/folate/NS_patient-folate/DSECTION=dosing. Accessed: August 5, 2011.

  17. Uhl W, Nolting A, Gallemann D, Hecht S, Kovar A. Changes in blood pressure after administration of hydroxocobalamin: relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers. Clin Toxicol (Phila). 2008 Jul. 46(6):551-9; discussion 576-7. [Medline].

  18. McEvoy GK (ed). American Hospital Formulary Service - Drug Information 2000. Bethesda, MD: American Society of Health-System Pharmacists Inc.; 2000.

 
Previous
Next
 
Megaloblastic anemia. View of red blood cells
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.